在状体瘤中缺氧信号通路
Kangxi Cao1, Wanzhong Yuan1, Chaofan Hou1
1Department of Neurosurgery, Peking University Third Hospital, Beijing 100191, China.
Cancers
|February 10, 2024
概括
状体瘤 (CBTs) 涉及与缺氧相关的信号通路. 了解酸脱酶 (SDH) 和低氧诱导因子 (HIF) 的作用是CBT瘤发生和潜在治疗的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 状体瘤 (CBT) 很少见,通常无症状,但在生长后可能引起症状.
- CBT的病因与高海拔,慢性缺氧 (例如COPD) 和家族遗传有关.
- 糖酸脱酶 (SDH) 基因的突变与CBT和细胞缺氧有关.
研究的目的:
- 系统地审查低氧信号通路和标记在CBT启动和进展中的作用.
- 探索这些途径对CBT瘤发生和潜在的治疗策略的影响.
- 巩固目前对CBT中低氧相关分子机制的理解.
主要方法:
- 系统性文献综述,重点关注心血管瘤中缺氧信号通路和标记物.
- 对基因突变 (SDH,HIF) 的分析及其对细胞过程的影响.
- 检查关键信号分子,包括VEGFs和炎症性细胞因子 (ICs).
主要成果:
- SDH突变,特别是SDHB和SDHD,与CBT,转移和多重瘤有关.
- 缺氧诱导因子 (HIF) 家族成员调节CBT中的血管生成和细胞增生.
- 在CBT的发展和对缺氧的反应中,VEGF和炎症性细胞因子 (ICs) 是至关重要的.
结论:
- 包括SDH,HIF,VEGF和IC在内的缺氧信号通路是CBT启动和进展的组成部分.
- 针对低氧途径为CBT提供了潜在的治疗途径.
- 对缺氧相关信号的进一步研究可以揭示新的治疗策略,并提高放射治疗的疗效.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K